FAQ on Quantum BioPharma Ltd.'s Submission of MS Drug Candidate to UK ILAP Program
Summary
Quantum BioPharma Ltd. has submitted its multiple sclerosis drug candidate, Lucid-MS, to the UK's ILAP program to accelerate its development and approval, marking a significant step in its global strategy to address neurodegenerative disorders.
What is Quantum BioPharma Ltd.’s recent announcement about?
Quantum BioPharma Ltd. announced that its subsidiary, Huge Biopharma Australia Pty Ltd., has submitted its patented multiple sclerosis drug candidate, Lucid-21-302 (Lucid-MS), to the UK’s Innovative Licensing and Access Pathway (ILAP) Passport program to accelerate its development and approval.
Why is the submission to the UK’s ILAP program significant?
The submission to the UK’s ILAP program is significant because it aims to accelerate access to groundbreaking treatments like Lucid-MS by streamlining the drug development and approval process, which is crucial for patients suffering from multiple sclerosis.
What is Lucid-MS?
Lucid-MS is a first-in-class therapy developed by Quantum BioPharma Ltd. that targets demyelination in multiple sclerosis, shown to prevent and reverse myelin degradation in preclinical models.
How does the ILAP program work?
The ILAP program unites developers, regulators, and the NHS to streamline the drug development and approval process, aiming to accelerate access to innovative treatments for patients.
Who is involved in this announcement?
Quantum BioPharma Ltd., its subsidiary Huge Biopharma Australia Pty Ltd., and the UK’s ILAP program are involved in this announcement, focusing on the development and approval of Lucid-MS for multiple sclerosis treatment.
Where can I find more information about Quantum BioPharma Ltd.?
More information about Quantum BioPharma Ltd. is available in the company’s newsroom at https://ibn.fm/QNTM and through its subsidiary’s website at https://www.unbuzzd.com.
What are the implications of this submission for patients with multiple sclerosis?
The submission of Lucid-MS to the ILAP program could significantly accelerate the availability of a novel treatment for multiple sclerosis, offering hope for preventing and reversing myelin degradation, the underlying mechanism of the disease.
What other projects is Quantum BioPharma Ltd. involved in?
Quantum BioPharma Ltd. is also involved in the development of treatments for neurodegenerative and metabolic disorders, alcohol misuse disorders, and maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 99211